AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12947367
Drug: PEG-Sak at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-Sak at 0.01 mg/kg
Trial: 12947367
Drug: PEG-Sak at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-Sak at doses of 0.01875 to 0.0375 mg/kg (n = 314)
Trial: 12947367
Drug: PEG-Sak at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-Sak at 0.05 mg/kg (n = 23)
Trial: 6352036
Drug: Propranolol-hydralazine combination
RxNorm normalized name: dihydralazine / propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol-hydralazine combination (40 mg/25 mg, 80 mg/25 mg, 80 mg/50 mg, 120 mg/50 mg, 160 mg/50 mg, 160 mg/100 mg)
Trial: 6352036
Drug: Propranolol-hydralazine combination
RxNorm normalized name: dihydralazine / propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol-hydralazine combination
Trial: 16521849
Drug: Ribose (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribose (3 g ribose + 150 microg folate)
Trial: 16521849
Drug: Placebo (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (150 mL)
Trial: 10919421
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion
Trial: 10520911
Drug: Paravertebral infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paravertebral infusion
Trial: 1778538
Drug: Sustained-release acebutolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release acebutolol (500 mg/day)
Trial: 1778538
Drug: Conventional acebutolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acebutolol (200 mg tid)
Trial: 30707227
Drug: Thyrotropin suppression
RxNorm normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin suppression through levothyroxine therapy
Trial: 21931661
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 mg QD (Low)
Trial: 21931661
Drug: Aprepitant 250
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 250 mg QD (High)
Trial: 17329466
Drug: Olanzapine (7.5-30.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (7.5-30.0 mg/day)
Trial: 10930903
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg daily plus amoxycillin 1 g b.d. and clarithromycin 250 mg b.d. for 1 week (Group PAC)
Trial: 10930903
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg daily for 1 month (Group P)
Trial: 9207754
Drug: Low-dose Convit
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Convit vaccine plus MDT
Trial: 9207754
Drug: Killed Mycobacterium
RxNorm normalized name: Heat Killed Mycobacterium W Immunomodulator
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed Mycobacterium leprae vaccine plus MDT
Trial: 1539776
Drug: omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 40 mg 12 hourly alone
Trial: 1539776
Drug: omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 40 mg 12 hourly with sodium citrate
Trial: 1539776
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg 6 hourly with sodium citrate
Trial: 26894485
Drug: loratadine 10
RxNorm normalized name: loratadine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loratadine 10 mg daily for 7 days
Trial: 18091289
Drug: Telephone-only motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-only motivational interviewing (MI) intervention with a pedometer and monthly MI telephone calls over 6 months
Trial: 15939582
Drug: Zileuton (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton (600 mg) four times a day for 5 days
Trial: 11074181
Drug: Levetiracetam 1000
RxNorm normalized name: levetiracetam 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 1000 mg per day
Trial: 11074181
Drug: Levetiracetam 2000
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam 2000 mg per day
Trial: 11074181
Drug: Levetiracetam 3000
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam 3000 mg per day
Trial: 11074181
Drug: Levetiracetam 4000
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam 4000 mg per day
Trial: 11074181
Drug: Levetiracetam (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (any dose)
Trial: 9004249
Drug: NG‐nitro‐L‐arginine methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐nitro‐L‐arginine methyl ester (L‐NAME) 40 micrograms/kg injected plus 50 micrograms/kg infused over 60 min
Trial: 9004249
Drug: NG‐nitro‐L‐arginine methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐nitro‐L‐arginine methyl ester (L‐NAME)
Trial: 1627424
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cyclophosphamide, methotrexate, fluorouracil, and prednisone for six cycles)
Trial: 7458118
Drug: Cephalozoline administered
RxNorm normalized name: cephaloridine
DrugBank: Cefaloridine (DB09008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalozoline administered 1 hour before and 5 and 12 hours after surgery
Trial: 7458118
Drug: Thiamphenicol administered
RxNorm normalized name: thiamphenicol
DrugBank: Thiamphenicol (DB08621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamphenicol administered 1 hour before and 5 and 12 hours after surgery
Trial: 7458118
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cephalozoline and thiamphenicol administered 1 hour before and 5 and 12 hours after surgery
Trial: 7458118
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics administered (control group)
Trial: 22674156
Drug: Intravenous butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous butorphanol
Trial: 24021297
Drug: Formula-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula-based dosing of Genotropin® GH (0.18 to 0.7 mg/kg/week)
Trial: 24021297
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of Genotropin® (0.37 mg/kg/week)
Trial: 20844485
Drug: Omeprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (80 mg) with clopidogrel (300 mg loading dose/75 mg/day maintenance dose)
Trial: 20844485
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose/75 mg/day maintenance dose) administered 12 hours apart from omeprazole (80 mg)
Trial: 20844485
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg loading dose/150 mg/day maintenance dose) with omeprazole (80 mg)
Trial: 20844485
Drug: Pantoprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (80 mg) with clopidogrel (300 mg loading dose/75 mg/day maintenance dose)
Trial: 16918592
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (IDet) 0.3 U/kg
Trial: 16918592
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (IDet) 0.6 U/kg
Trial: 16918592
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (IDet) 1.2 U/kg
Trial: 16918592
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin 0.3 IU/kg
Trial: 16918592
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin 0.6 IU/kg
Trial: 16918592
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin 1.2 IU/kg
Trial: 7481865
Drug: Various adjuvant
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various adjuvant treatments
Trial: 17434599
Drug: Mood stabilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood stabilizer treatment
Trial: 20834185
Drug: Low-dose Erythropoietin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Erythropoietin (6,000 IU during PCI, 24h and 48h)
Trial: 15803314
Drug: Perindopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (2 mg/day; n = 20)
Trial: 15803314
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg/day; n = 20)
Trial: 10329810
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 25 micrograms to 500 micrograms, twice daily
Trial: 7851579
Drug: Oral 17
RxNorm normalized name: polyoxypropylene (17)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17 beta-E2 with high dose of CPA
Trial: 7851579
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta-E2 with high dose of CPA
Trial: 7015912
Drug: Budesonide (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (topical corticosteroid)
Trial: 31848231
Drug: Immediate disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate disease-modifying therapy (DMT)
Trial: 31848231
Drug: Delayed disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed disease-modifying therapy (DMT)
Trial: 28640124
Drug: Anesthesia machine:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia machine: Excel, Avance, Cato, Primus with low-flow anesthesia (0.5, 1, and 4 L/min)
Trial: 28640124
Drug: Anesthesia machine:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia machine: Cato and Primus with fresh gas flow of 4 L/min
Trial: 24007540
Drug: Birth Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth Preparation Program (BPP)
Trial: 18704426
Drug: rhTNFR:Fc (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTNFR:Fc (25 mg, subcutaneous injection, twice weekly)
Trial: 3529677
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (daily dose 400 I.E. d‐alpha‐tocopherylacetate)
Trial: 31026298
Drug: Social and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social and preventive medicine consultation (intervention group)
Trial: 28760534
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized Japanese cedar pollen extract
Trial: 26991399
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg twice daily (b.d.)
Trial: 26991399
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg daily
Trial: 26991399
Drug: esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole 20 mg b.d.
Trial: 26991399
Drug: esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole 20 mg daily
Trial: 20096622
Drug: Liposomal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal spray
Trial: 18671464
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment options including surgery, radiotherapy, and systemic chemotherapy.
Trial: 15972867
Drug: Standard 24-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 24-week regimen of peginterferon alfa-2b at a dose of 1.0 mug per kilogram weekly plus ribavirin at a dose of 1000 mg or 1200 mg daily.
Trial: 8765493
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP) treatment, 30 mg/kg orally for 4 days
Trial: 8765493
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP) treatment
Trial: 8765493
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HDMP treatment)
Trial: 1532974
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug therapy for maintenance of remission
Trial: 25670541
Drug: C-HART (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-HART (30 Gy/2 Gy daily followed by twice-daily 1.4 Gy to a total of 70.6 Gy with concurrent mitomycin C/5-FU)
Trial: 25670541
Drug: HART (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HART (16 Gy/2 Gy daily followed by twice-daily 1.4 Gy to a total dose of 77.6 Gy alone)
Trial: 22077535
Drug: Self-report administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-report administration of the Post-Concussion Scale
Trial: 22077535
Drug: Interview administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interview administration of the Post-Concussion Scale
Trial: 18754005
Drug: Delta 9-tetrahydrocannabinol
RxNorm normalized name: delta 9-tetrahydrocannabinol acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta 9-tetrahydrocannabinol (THC) inhalation
Trial: 14695462
Drug: Warfarin (anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (anticoagulation intensity with INR > or = 1.5)
Trial: 14695462
Drug: Warfarin (INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR 1.5-1.9)
Trial: 14695462
Drug: Warfarin (INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR > or = 2.0)
Trial: 9385884
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rt-PA intravenous bolus followed by 80 mg i.v. infusion over 60 min (regimen A)
Trial: 9385884
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg rt-PA over 90 min (C)
Trial: 9385884
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rt-PA over 90 min (D)
Trial: 26582883
Drug: rHPIV‐1/84/del 170/942A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHPIV‐1/84/del 170/942A vaccine
Trial: 23732788
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection of propofol by a university‐degreed anesthesia registered nurse based on BIS values (Group 1)
Trial: 23732788
Drug: Usual scheme
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual scheme of intravenous sedation with midazolam and fentanyl administered by the endoscopic team (Group 0)
Trial: 16979998
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) prophylaxis (300 mg/d for patients >35 kg and 5 mg/kg/d for patients <35 kg) with Pyridoxine 50 mg/d for 1 year
Trial: 14663472
Drug: Selenium-vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenium-vitamin E supplement for at least 6 months
Trial: 14663472
Drug: No selenium-vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No selenium-vitamin E supplement
Trial: 14663472
Drug: Selenium-vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenium-vitamin E supplements
Trial: 9773927
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: omeprazole 20 mg once daily for 2 weeks, amoxicillin 500 mg thrice daily, metronidazole 250 mg thrice daily, roxithromycin 150 mg twice daily for 1 week
Trial: 9773927
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: same antibiotic treatment as group 1 for 1 week, plus omeprazole treatment for 2 weeks
Trial: 8143059
Drug: Lysine-aspirin inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine-aspirin inhalation
Trial: 3146893
Drug: Demonstration dose
RxNorm normalized name: OCTREOTIDE SA DEMONSTRATION KIT INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demonstration dose of sublingual nitroglycerin administered during the office visit
Trial: 3146893
Drug: No demonstration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No demonstration dose (control group)
Trial: 3146893
Drug: Demonstration dose
RxNorm normalized name: OCTREOTIDE SA DEMONSTRATION KIT INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demonstration dose of sublingual nitroglycerin
Trial: 2884229
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment designed to achieve and maintain near-normal glucose levels (n = 18)
Trial: 2884229
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n = 15)
Trial: 2884229
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with stimulated C-peptide levels greater than 0.2 pmol/mL
Trial: 31647147
Drug: EPA-enriched supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-enriched supplement
Trial: 23703730
Drug: Web-based acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based acceptance and commitment therapy (ACT) intervention (WebQuit.org)
Trial: 21499934
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 100% oxygen for 50 minutes (Oxy50)
Trial: 21499934
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 100% oxygen followed by a 30-minute period after inhalation (After)
Trial: 21499934
Drug: Before inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before inhalation of pure oxygen (Before)
Trial: 21499934
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of air (Control group) for 20 minutes (Oxy20)
Trial: 19459553
Drug: Bupivacaine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (500 mg) loaded microspheres
Trial: 19459553
Drug: Bupivacaine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (100 mg) and Ropivacaine (150 mg)
Trial: 15302718
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) methylprednisolone (160 mg single dose)
Trial: 15302718
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (8-day tapering of total 160 mg)
Trial: 11451713
Drug: Dietary supplements,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplements, either alone or in combination with hormonal treatment
Trial: 1117460
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5-fluorouracil (5-FU), methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine
Trial: 26476489
Drug: lithium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lithium plus optimized personalized treatment (OPT)
Trial: 26476489
Drug: optimized personalized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optimized personalized treatment (OPT) without lithium
Trial: 23503546
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch application followed by oral levodopa/benserazide, 100/25 mg
Trial: 23503546
Drug: Nicotine and
RxNorm normalized name: lovastatin and nicotinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine and cotinine at 0.1 μmol/L
Trial: 19339089
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with a standard trivalent inactivated influenza vaccine
Trial: 9628086
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (1.3 micrograms/kg)
Trial: 6989171
Drug: 1 alpha‐OHD3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 alpha‐OHD3 (1 microgram/day) + 2.5 g CaCO3
Trial: 26424587
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg melatonin